(Q38391086)

2 September 2017

0 references

1 reference

title

EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease (English)

1 reference

2 September 2017

0 references

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Charlotte Cordonnier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Daniela Galimberti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

José Luis Molinuevo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Dorota Religa

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jonathan M Schott

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sandro Sorbi

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

6

T Fladby

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

15

P Scheltens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

E Hofer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

F H Bouwman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

K Buerger

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

J Georges

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

M T Heneka

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

J Hort

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

J Laczó

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

R Schmidt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

25 March 2015

1 reference

European Journal of Neurology

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

889-898

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

7 June 2020

cites work

1 reference

Combination therapy for Alzheimer's disease

21 January 2018

1 reference

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

21 January 2018

1 reference

Long-term course and effectiveness of combination therapy in Alzheimer disease

21 January 2018

1 reference

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

21 January 2018

1 reference

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

21 January 2018

1 reference

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

21 January 2018

1 reference

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.

21 January 2018

1 reference

Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

21 January 2018

1 reference

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

21 January 2018

1 reference

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012.

21 January 2018

1 reference

GRADE guidelines: 2. Framing the question and deciding on important outcomes.

21 January 2018

1 reference

The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors

21 January 2018

1 reference

Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative

21 January 2018

1 reference

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.

21 January 2018

1 reference

Cholinesterase inhibitors: A new class of psychotropic compounds

21 January 2018

1 reference

The incremental direct costs associated with behavioral symptoms in AD.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ENE.12707

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25808982%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference